Cargando…
Comparison of sleep microarchitecture in screen failure subjects with insomnia complaints and randomized subjects from two phase 3 studies on insomnia disorder
INTRODUCTION: Daridorexant, a dual orexin receptor antagonist, was shown to be effective and safe in improving sleep and daytime functioning in subjects with insomnia in two Phase 3 studies. All patients screened had subjective insomnia, but many did not meet the study eligibility criteria. OBJECTIV...
Autores principales: | Di Marco, T., Dauvilliers, Y., Scammell, T., Djonlagic, I., Datta, A., Zammit, G., Seboek Kinter, D., Tjiptarto, N., Donoghue, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596388/ http://dx.doi.org/10.1192/j.eurpsy.2023.612 |
Ejemplares similares
-
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
por: Di Marco, Tobias, et al.
Publicado: (2023) -
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
por: Kunz, Dieter, et al.
Publicado: (2022) -
Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)
por: Hudgens, Stacie, et al.
Publicado: (2020) -
Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)
por: Hudgens, Stacie, et al.
Publicado: (2023) -
Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trials
por: Heidenreich, Sebastian, et al.
Publicado: (2022)